Retatrutide
Also known as: Triple-G agonist · LY3437943
An investigational once-weekly agonist that acts on three hormone receptors at once — GLP-1, GIP, and glucagon — and is studied in the context of appetite and metabolic regulation.
Class
GLP-1 / GIP / glucagon agonist
Default unit
mg
Common route
Subcutaneous
Typical half-life
~6 days
Frequency
Once weekly
Commonly associated areas
Illustrative map of the body systems Retatrutide is most often discussed in relation to. Relative emphasis only — not a measure of efficacy or a medical claim.
Proposed mechanisms / pathways
What is Retatrutide?
Retatrutide (development code LY3437943) is an investigational triple-receptor agonist — a single molecule that activates the GLP-1, GIP, and glucagon receptors at the same time. The first two are the same incretin pathways targeted by GLP-1 and dual GLP-1/GIP agonists, while the added glucagon activity is the feature that sets it apart. Its long half-life of roughly six days supports a once-weekly cadence.
How it is thought to work
By engaging three hormone receptors at once, retatrutide is thought to combine appetite and blood-sugar effects similar to other incretin agonists with the added influence of glucagon signaling, which is proposed to affect energy expenditure and metabolism. The practical result discussed in studies is a gradual reduction in appetite and body weight over weeks rather than any immediate change. These mechanisms remain under active investigation.
Educational only — not medical advice
Retatrutide is an investigational compound that has not been approved for general human use and remains in clinical trials. Nothing here is a recommendation, dose, or medical claim — consult a qualified healthcare provider before considering any protocol.
Tracking Retatrutide in LynkDose
Because retatrutide is titrated — stepped up gradually to let the body adjust — record-keeping is unusually valuable. In LynkDose, log each weekly dose with its date, mark when the dose increases, do a consistent weekly weigh-in, and note appetite changes and any side effects. With that history, a plateau or a reaction becomes something you can actually see and discuss rather than guess at.
Commonly discussed for
- Appetite and craving regulation
- Weight-management research protocols
- Blood-sugar and metabolic markers
Often stacked: Generally studied on its own as a single triple-agonist molecule rather than stacked, though it is often compared with other incretin compounds like semaglutide.
How to track Retatrutide in LynkDose
Retatrutide is typically titrated upward over weeks, so logging the date of every dose change is key — it lets you connect weight, appetite, and any side effects to a specific dose step.
Deeper read: Tracking GLP-1 Peptides (Semaglutide & Tirzepatide)
Not medical advice
This page is educational and does not recommend, prescribe, or dose any compound. Many peptides are research chemicals not approved for general human use. Always consult a qualified healthcare provider and follow the laws in your area.